Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 10, 2013Separate Study Demonstrates PROMUS Element Stent has Significantly Less Vessel Straightening than the Xience V® Stent
Boston Scientific Corporation (NYSE: BSX) reported clinical endpoint data from the PLATINUM workhorse clinical trial comparing the safety and effectiveness of the PROMUS Element™...
-
May 9, 2013
Boston Scientific Corporation (NYSE: BSX) reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN® Left Atrial Appendage (LAA) Closure device was...
-
May 6, 2013
Boston Scientific Corporation (NYSE: BSX) completed a first-in-human clinical trial utilizing the IntellaTip MiFi? XP Ablation Catheter for the treatment of type 1 atrial flutter, an arrhythmia...
-
Mar 9, 2013
Boston Scientific Corporation (NYSE: BSX) reports preliminary data in the PREVAIL clinical trial met two out of three co-primary endpoints. The PREVAIL trial evaluates safety and efficacy of the...
-
Mar 9, 2013WATCHMAN® Device Continues to Demonstrate Positive Clinical Outcomes for Patients with Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) announces the preliminary analysis of the PREVAIL clinical trial data is now available on TCTMD at https://www.tctmd.com/show.aspx?id=118115. PREVAIL...
-
Mar 6, 2013First Presentation of the Preliminary Results of All Three Co-Primary Endpoints to be Revealed During The American College of Cardiology 2013 Annual Scientific Sessions
The Boston Scientific Corporation (NYSE: BSX) PREVAIL clinical trial results will be presented in a Late-Breaking Clinical Trial presentation at the 62nd Annual Scientific Sessions of the American...
-
Feb 12, 2013The Next Advance in Durable Polymer Stent Technology from Boston Scientific is Now Available in Europe and Other Select Geographies
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable...
-
Jan 29, 2013
Organizations Team up to Raise awareness and Make a Call to Action for European Governments to Develop Comprehensive Chronic Pain Treatment Programs Boston Scientific Corporation (NYSE: BSX) today...
-
Jan 16, 2013
The first patient has been treated in the Boston Scientific Corporation (NYSE: BSX) ZERO AF clinical trial to evaluate the safety and effectiveness of the Blazer® Open-Irrigated Temperature...
-
Jan 13, 2013Organisationen verbünden sich, um das Bewusstsein zu stärken und die europäischen Regierungen aufzurufen, neue und umfassende Programme zur Behandlung von chronischen Schmerzen auf den Weg zu bringen
Boston Scientific Corporation (NYSE: BSX) hat heute die Resultate einer europaweiten Befragung von mehr als 1.000 von chronischen Schmerzen Betroffenen veröffentlicht; die Ergebnisse legen nahe,...